石药创新 reported revenue of ¥3.24B for the period ended 2026-06-30, +208.7% year on year. Net income was ¥1.55B, a 47.9% net margin on a 76.7% gross margin. The largest revenue line is 生物制药 at 70% of the total. Free cash flow for the period was ¥2.81B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥3.24B | +208.7% |
| Gross profit | ¥2.49B | — |
| Operating income | ¥1.57B | — |
| Net income | ¥1.55B | — |
| Gross margin | 76.7% | Net margin 47.9% |
| Revenue Q/Q | +287.5% | — |
| Segment | Revenue | Share |
|---|---|---|
| 生物制药 | ¥2.26B | 69.8% |
| 功能性原料及保健食品 | ¥0.95B | 29.4% |
| 其他(补充) | ¥0.03B | 0.8% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.75B | 23.3% |
| R&D | ¥0.66B | 20.5% |
| SG&A | ¥0.22B | 6.9% |
| Tax & other | ¥0.02B | 0.6% |
| Item | Amount |
|---|---|
| Total assets | ¥8.71B |
| Total liabilities | ¥4.35B |
| Shareholders' equity | ¥4.36B |
| Equity / assets | 50.0% |
| Operating cash flow | ¥2.96B |
| Capital expenditure | ¥0.14B |
| Free cash flow | ¥2.81B |
| Cash conversion (OCF / net income) | 179% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
每日互动 ・ 震安科技 ・ 迪普科技 ・ 德方纳米 ・ 新媒股份 ・ 智莱科技 ・ 运达股份 ・ 拉卡拉 ・ 倍杰特 ・ 三角防务 ・ 帝尔激光 ・ 中简科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies